World Health Organization & Mapp Biopharmaceutical

World Health Organization: The World Health Organization is sponsoring and coordinating the clinical trial for Ebola treatments in the Democratic Republic of the Congo, aiming to find effective therapeutics for the Bundibugyo strain.

Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, an experimental monoclonal antibody treatment being tested in the Ebola clinical trial. The United States government has funded research for this drug.

World Health Organization: The World Health Organization (WHO) has added the first molecular diagnostic test for Bundibugyo ebolavirus to its Emergency Use Listing, accelerating access to reliable diagnostic tools for early detection and response to the outbreak. WHO is a key player in coordinating global health responses and ensuring quality health products.

Mapp Biopharmaceutical: Mapp Biopharmaceutical's experimental MBP134 antibody is being evaluated in a treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, either as a standalone treatment or in combination with Gilead Sciences' remdesivir.